Schmidt, Wolfgang E.

Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6)

Buse, J. B., Rosenstock, J., Sesti, G., Schmidt, W. E., Montanya, E., Brett, J. H., Zychma, M., & Blonde, L. (2009) · The Lancet

Diabetes Treatment and ManagementDiabetes Management and Research

Cited by 1,503

Obeticholic acid for the treatment of non-alcoholic steatohepatitis: Interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial

Younossi, Z. M., Ratziu, V., Loomba, R., Rinella, M., Anstee, Q. M., Goodman, Z., Bedossa, P., Geier, A., Beckebaum, S., Newsome, P. N., et al. (2019) · The Lancet

Liver Disease Diagnosis and TreatmentLiver Diseases and Immunity

Cited by 1,277

Dipeptidyl‐peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon‐like peptide‐1(7–36)amide, peptide histidine methionine and is responsible for their degradation in human serum

MENTLEIN, R., GALLWITZ, B., & SCHMIDT, W. E. (1993) · European Journal of Biochemistry

Peptidase Inhibition and AnalysisDiabetes Treatment and Management

Cited by 1,161

Normalization of glucose concentrations and deceleration of gastric emptying after solid meals during intravenous glucagon-like peptide 1 in patients with type 2 diabetes

Meier, J. J., Gallwitz, B., Salmen, S., Goetze, O., Holst, J. J., Schmidt, W. E., & Nauck, M. A. (2003) · The Journal of Clinical Endocrinology & Metabolism

Diabetes Treatment and ManagementPancreatic function and diabetes

Cited by 369

Secretion, Degradation, and Elimination of Glucagon-Like Peptide 1 and Gastric Inhibitory Polypeptide in Patients with Chronic Renal Insufficiency and Healthy Control Subjects

Meier, J. J., Nauck, M. A., Kranz, D., Holst, J. J., Deacon, C. F., Gaeckler, D., Schmidt, W. E., & Gallwitz, B. (2004) · Diabetes

Diabetes Treatment and ManagementPancreatic function and diabetes

Cited by 334

Gastric inhibitory polypeptide (GIP) dose-dependently stimulates glucagon secretion in healthy human subjects at euglycaemia

Meier, J. J., Gallwitz, B., Siepmann, N., Holst, J. J., Deacon, C. F., Schmidt, W. E., & Nauck, M. A. (2003) · Diabetologia

Pancreatic function and diabetesDiabetes Treatment and Management

Cited by 314

Glucagon-like peptide 1 abolishes the postprandial rise in triglyceride concentrations and lowers levels of non-esterified fatty acids in humans

Meier, J. J., Gethmann, A., Götze, O., Gallwitz, B., Holst, J. J., Schmidt, W. E., & Nauck, M. A. (2006) · Diabetologia

Diabetes Treatment and ManagementRegulation of Appetite and Obesity

Cited by 276

Partial pancreatectomy in adult humans does not provoke β-cell regeneration

Menge, B. A., Tannapfel, A., Belyaev, O., Drescher, R., Müller, C., Uhl, W., Schmidt, W. E., & Meier, J. J. (2008) · Diabetes

Pancreatic function and diabetesDiabetes and associated disorders

Cited by 173

Incretin-based glucose-lowering medications and the risk of acute pancreatitis and malignancies: A meta-analysis based on cardiovascular outcomes trials

Abd El Aziz, M., Cahyadi, O., Meier, J. J., Schmidt, W. E., & Nauck, M. A. (2020) · Diabetes, Obesity and Metabolism

Diabetes Treatment and ManagementPharmacovigilance and Adverse Drug Reactions

Cited by 160

Secretion of incretin hormones (GIP and GLP-1) and incretin effect after oral glucose in first-degree relatives of patients with type 2 diabetes

Nauck, M. A., El-Ouaghlidi, A., Gabrys, B., Hücking, K., Holst, J. J., Deacon, C. F., Gallwitz, B., Schmidt, W. E., & Meier, J. J. (2004) · Regulatory Peptides

Pancreatic function and diabetesDiabetes Treatment and Management

Cited by 137

The glucagon-like peptide-1 metabolite GLP-1-(9–36) amide reduces postprandial glycemia independently of gastric emptying and insulin secretion in humans

Meier, J. J., Gethmann, A., Nauck, M. A., Götze, O., Schmitz, F., Deacon, C. F., Gallwitz, B., Schmidt, W. E., & Holst, J. J. (2006) · American Journal of Physiology-Endocrinology and Metabolism

Diabetes Treatment and ManagementPancreatic function and diabetes

Cited by 104

Intravenous glucagon-like peptide 1 normalizes blood glucose after major surgery in patients with type 2 diabetes

Meier, J. J., Weyhe, D., Michaely, M., Senkal, M., Zumtobel, V., Nauck, M. A., Holst, J. J., Schmidt, W. E., & Gallwitz, B. (2004) · Critical Care Medicine

Hyperglycemia and glycemic control in critically ill and hospitalized patientsDiabetes Treatment and Management

Cited by 89

Proinsulin levels in patients with pancreatic diabetes are associated with functional changes in insulin secretion rather than pancreatic β-cell area

Breuer, T. G. K., Menge, B. A., Banasch, M., Uhl, W., Tannapfel, A., Schmidt, W. E., Nauck, M. A., & Meier, J. J. (2010) · European Journal of Endocrinology

Pancreatic function and diabetesPancreatitis Pathology and Treatment

Cited by 20

Incretin‐based glucose‐lowering medications and the risk of acute pancreatitis and/or pancreatic cancer: Reassuring data from cardio‐vascular outcome trials

Nauck, M. A., Meier, J. J., & Schmidt, W. E. (2017) · Diabetes, Obesity and Metabolism

Diabetes Treatment and ManagementPancreatic and Hepatic Oncology Research

Cited by 19